Literature DB >> 15769642

Insulin resistance in NASH.

J Choudhury1, A J Sanyal.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease observed in the clinical practice of hepatology. The coexistence of metabolic syndrome in this cohort of patients has made insulin resistance central to the pathogenesis of these disorders. The metabolic consequence of insulin resistance is impaired hepatic glucose output and abnormal lipid handling. In the face of continued metabolic insults the normal hepatic regulatory mechanism gets overwhelmed and fat accumulates in the hepatocytes. The subsequent fate of steatotic hepatocytes depends on the capacity of additional factors such as adipocytokines and toxicity induced by the free fatty acids themselves to induce inflammatory response. This latter process is responsible for the producing the phenotype of non-alcoholic steatohepatitis (NASH). Irrespective of the process by which these phenotypic response occurs, it is now universally accepted that in the absence of insulin resistance the spectrum of changes one associates with NAFLD does not develop. In this review we will discuss the various processes that are involved in the pathogenesis of NAFLD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15769642     DOI: 10.2741/1636

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  15 in total

1.  Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers.

Authors:  Qin Feng; Susan S Baker; Wensheng Liu; Ricardo A Arbizu; Ghanim Aljomah; Maan Khatib; Colleen A Nugent; Robert D Baker; Trudy M Forte; Yiyang Hu; Lixin Zhu
Journal:  Pathology       Date:  2015-06       Impact factor: 5.306

2.  Preventive effects of dietary walnuts on high-fat-induced hepatic fat accumulation, oxidative stress and apoptosis in mice.

Authors:  Youngshim Choi; Mohamed A Abdelmegeed; Byoung-Joon Song
Journal:  J Nutr Biochem       Date:  2016-09-22       Impact factor: 6.048

3.  A maternal "junk food" diet in pregnancy and lactation promotes nonalcoholic Fatty liver disease in rat offspring.

Authors:  Stéphanie A Bayol; Bigboy H Simbi; Robert C Fowkes; Neil C Stickland
Journal:  Endocrinology       Date:  2010-03-05       Impact factor: 4.736

Review 4.  Insulin sensitizers for the treatment of non-alcoholic fatty liver disease.

Authors:  Zeynel Abidin Ozturk; Abdurrahman Kadayifci
Journal:  World J Hepatol       Date:  2014-04-27

5.  Hepatic lipid metabolism changes in short- and long-term prehepatic portal hypertensive rats.

Authors:  Maria-Angeles Aller; Elena Vara; Cruz García; Maria-Paz Nava; Alejandra Angulo; Fernando Sánchez-Patán; Ana Calderón; Patri Vergara; Jaime Arias
Journal:  World J Gastroenterol       Date:  2006-11-14       Impact factor: 5.742

6.  Signal transduction mechanism of TRB3 in rats with non-alcoholic fatty liver disease.

Authors:  Yu-Gang Wang; Min Shi; Ting Wang; Ting Shi; Jue Wei; Na Wang; Xi-Mei Chen
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

Review 7.  Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment.

Authors:  Tim C M A Schreuder; Bart J Verwer; Carin M J van Nieuwkerk; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

8.  Change of intestinal mucosa barrier function in the progress of non-alcoholic steatohepatitis in rats.

Authors:  Sheng Li; Wan-Chun Wu; Chi-Yi He; Zhen Han; Dao-You Jin; Lin Wang
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

9.  Environmental toxin-linked nonalcoholic steatohepatitis and hepatic metabolic reprogramming in obese mice.

Authors:  Ratanesh Kumar Seth; Ashutosh Kumar; Suvarthi Das; Maria B Kadiiska; Gregory Michelotti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Toxicol Sci       Date:  2013-05-02       Impact factor: 4.849

10.  Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats.

Authors:  Wan-Chun Wu; Wei Zhao; Sheng Li
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.